BACKGROUND: Highly active antiretroviral therapy has dramatically altered progression of HIV infection and significantly improved patients' quality of life. However, drug resistance with consequent treatment failure raises the need for much more expensive and toxic second-line regimens. Thus, this study aimed at investigating the predictors of virologic failure among adults in Northeast Ethiopia. METHODS: A retrospective cohort study was carried out among adults who started first-line antiretroviral treatment from September 2005 to January 2018. Data were collected from patients' medical records, entered and validated using EpiData version 3.1 and then exported to SPSS version 20 for analysis. Binary logistic regression was carried out; odds ratio with 95% CI was used to identify covariates associated with virologic failure. Statistical significance was considered at p-value <0.05. RESULTS: A total of 384 patients with mean age of 35.73±9.44 years were consecutively enrolled; of which, 213 (55.5%) were females, 255 (66.4%) had WHO clinical stage III/IV, and 130 (33.9%) had baseline CD4 count <100 cells/mm3. Mean baseline CD4 count was 179 cells/mm3 (range: 2-853 cells), and 158 (41.1%) participants were on AZT/3TC/NVP. Virological failure was diagnosed among 61 (15.9%) patients. The mean time to virologic failure after initiation of ART was 63.80 months (range: 17-150 months). After adjusting for other confounders, risk of experiencing virologic failure was significantly associated with being divorced (AOR 3.40, 95% CI 1.20-9.59), being naïve to ART (AOR 2.55, 95% CI 1.23-5.28), low (<100) baseline CD4 count (AOR 2.39, 95% CI 1.03-5.54) and nonadherence (AOR 6.73, 95% CI 3.29-13.76). CONCLUSION: In this study, the prevalence of antiretroviral treatment failure was 15.9%. Being divorced, being naïve to antiretroviral therapy, low (<100 cells/mm3) baseline CD4 count and nonadherence were found to be significant predictors of virologic failure. ART programs should focus on early HIV diagnosis and ART initiation as well as enhanced adherence support.
BACKGROUND: Highly active antiretroviral therapy has dramatically altered progression of HIV infection and significantly improved patients' quality of life. However, drug resistance with consequent treatment failure raises the need for much more expensive and toxic second-line regimens. Thus, this study aimed at investigating the predictors of virologic failure among adults in Northeast Ethiopia. METHODS: A retrospective cohort study was carried out among adults who started first-line antiretroviral treatment from September 2005 to January 2018. Data were collected from patients' medical records, entered and validated using EpiData version 3.1 and then exported to SPSS version 20 for analysis. Binary logistic regression was carried out; odds ratio with 95% CI was used to identify covariates associated with virologic failure. Statistical significance was considered at p-value <0.05. RESULTS: A total of 384 patients with mean age of 35.73±9.44 years were consecutively enrolled; of which, 213 (55.5%) were females, 255 (66.4%) had WHO clinical stage III/IV, and 130 (33.9%) had baseline CD4 count <100 cells/mm3. Mean baseline CD4 count was 179 cells/mm3 (range: 2-853 cells), and 158 (41.1%) participants were on AZT/3TC/NVP. Virological failure was diagnosed among 61 (15.9%) patients. The mean time to virologic failure after initiation of ART was 63.80 months (range: 17-150 months). After adjusting for other confounders, risk of experiencing virologic failure was significantly associated with being divorced (AOR 3.40, 95% CI 1.20-9.59), being naïve to ART (AOR 2.55, 95% CI 1.23-5.28), low (<100) baseline CD4 count (AOR 2.39, 95% CI 1.03-5.54) and nonadherence (AOR 6.73, 95% CI 3.29-13.76). CONCLUSION: In this study, the prevalence of antiretroviral treatment failure was 15.9%. Being divorced, being naïve to antiretroviral therapy, low (<100 cells/mm3) baseline CD4 count and nonadherence were found to be significant predictors of virologic failure. ART programs should focus on early HIV diagnosis and ART initiation as well as enhanced adherence support.
Authors: Robert Gross; Benita Yip; Vincent Lo Re; Evan Wood; Christopher S Alexander; P Richard Harrigan; David R Bangsberg; Julio S G Montaner; Robert S Hogg Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Cecilia Ferreyra; Oliver Yun; Nell Eisenberg; Elena Alonso; Ashimosi S Khamadi; Matilu Mwau; Martha Kihara Mugendi; Ana Alvarez; Elena Velilla; Laurence Flevaud; Mireia Arnedo; David Dalmau; Paul Roddy; Andrea Bernasconi; Pedro Pablo Palma Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240
Authors: Maria F Nardell; Oluwatomi Adeoti; Carson Peters; Bernard Kakuhikire; Caroline Govathson-Mandimika; Lawrence Long; Sophie Pascoe; Alexander C Tsai; Ingrid T Katz Journal: J Int AIDS Soc Date: 2022-03 Impact factor: 5.396